Evidence map›Paper›PMID 41031006›Full record

ArticlebioRxiv : the preprint server for biology2025

IL-7-mediated expansion of autologous lymphocytes increases CD8

Kirit Singh, Kelly M Hotchkiss, Sarah L Cook, Pamy Noldner, Ying Zhou, Eliese M Moelker, Chelsea O Railton, Emily E Blandford, Bhairavy J Puviindran, Shannon E Wallace and 7 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Kirit SinghThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC, US.ORCID 0000-0002-0419-5381
Kelly M HotchkissThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC, US.
Sarah L CookThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC, US.
Pamy NoldnerThe Marcus Center for Cellular Cures, Duke University Medical Center, Durham, NC, US.
Ying ZhouThe Marcus Center for Cellular Cures, Duke University Medical Center, Durham, NC, US.
Eliese M MoelkerThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC, US.
Chelsea O RailtonThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC, US.
Emily E BlandfordThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC, US.
Bhairavy J PuviindranThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC, US.
Shannon E WallaceThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC, US.
Pamela K NorbergThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC, US.
Gary E ArcherThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC, US.
Beth H ShazThe Marcus Center for Cellular Cures, Duke University Medical Center, Durham, NC, US.
Katayoun AyasoufiThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC, US.ORCID 0000-0002-3797-0823
John H SampsonUniversity of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO.
Mustafa KhasrawThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC, US.
Peter E FecciThe Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, NC, US.

Funding

Targeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 AntibodyP50CA190991 · NCI · DUKE UNIVERSITY · PI ALI-OSMAN, FRANCIS, ASHLEY, DAVID M. · 2014 to 2023
$20.8M
Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent GlioblastomaP01CA225622 · NCI · DUKE UNIVERSITY · PI WEINHOLD, KENT J. · 2018 to 2022
$12.2M
Human EGFRvIII-specific BiTE for the treatment of GlioblastomaU01NS090284 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2015 to 2019
$5.2M
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)R01CA175517 · NCI · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A., SAMPSON, JOHN H. · 2015 to 2020
$3.1M
Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine EfficacyR01CA235612 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2019 to 2022
$2.0M
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor TherapyR01NS099463 · NINDS · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2017 to 2021
$1.7M
NCI NIH HHS P01 CA225622NCI NIH HHS P50 CA190991NCI NIH HHS R01 CA175517NCI NIH HHS R01 CA235612NINDS NIH HHS R01 NS099463NINDS NIH HHS U01 NS090284
6 · The paper itself

Abstract

The efficacy of T cell-activating therapies against glioma is limited by an immunosuppressive tumor microenvironment and tumor-induced T cell sequestration. We investigated whether peripherally infused non-antigen specific autologous lymphocytes (ALT) could accumulate in intracranial tumors. We observed that non-specific autologous CD8

Indexed as

Cell migration/adhesionImmunotherapyT cells

Identifiers

PMID41031006
PMCPMC12478354

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.